Govil Amit, Walsh R Carlin, Tevar Amit, Alloway Rita, Roy-Chaudhury Prabir, Mogilishetty Gautham, Wall Garth E, Brailey Paul, Girnita Alin, Woodle E Steve
The University of Cincinnati Medical Center, Cincinnati, Ohio, USA.
Clin Transpl. 2009:443-53.
This report presents the first experience with plasma cell-targeted therapy in treating antibody mediated rejection in pancreas transplant recipients. In this experience, bortezomib provided results similar to those previously reported in kidney transplant recipients, with the exception that DSA responses were not quite as dramatic in pancreas transplant recipients. However, even in patients with antibody mediated rejection refractory to standard therapies, significant responses were obtained with the proteasome inhibitor, bortezomib. These results confirm the potential for bortezomib-based therapies in pancreas transplant recipients, and also demonstrate that rejection following pancreas transplantation may require innovative approaches to provide optimal results.
本报告介绍了浆细胞靶向治疗在胰腺移植受者抗体介导排斥反应治疗中的首次经验。在此经验中，硼替佐米的治疗效果与先前在肾移植受者中报告的结果相似，不同之处在于胰腺移植受者的供体特异性抗体（DSA）反应不如肾移植受者显著。然而，即使是对标准治疗难治的抗体介导排斥反应患者，蛋白酶体抑制剂硼替佐米也取得了显著疗效。这些结果证实了基于硼替佐米的治疗方法在胰腺移植受者中的潜力，也表明胰腺移植后的排斥反应可能需要创新方法以获得最佳效果。
